Abstract
The Cannabis sativa plant has been used medicinally and recreationally for thousands of years, but recently only relatively some of its constituents have been identified. There are more than 550 chemical compounds in cannabis, with more than 100 phytocannabinoids being identified, including Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). These phytocannabinoids work by binding to the cannabinoid receptors, as well as other receptor systems. Also within cannabis are the aromatic terpenes, more than 100 of which have been identified. Cannabis and its constituents have been indicated as therapeutic compounds in numerous medical conditions, such as pain, anxiety, epilepsy, nausea and vomiting, and post-traumatic stress disorder. This chapter provides an overview of some of the biological effects of a number of the cannabinoids and terpenes, as well as discussing their known mechanisms of action and evidence of potential therapeutic effects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abrahamov A, Abrahamov A, Mechoulam R (1995) An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 56:2097–2102
Abrams DI, Couey P, Shade SB et al (2011) Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 90:844–851. https://doi.org/10.1038/clpt.2011.188
Adams R, Hunt M, Clark JH (1940) Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. I. J Am Chem Soc 62:196–200. https://doi.org/10.1021/ja01858a058
Ahmed SA, Ross SA, Slade D et al (2008) Cannabinoid ester constituents from high-potency Cannabis sativa. J Nat Prod 71:536–542. https://doi.org/10.1021/np070454a
Ahmed SA, Ross SA, Slade D et al (2015) Minor oxygenated cannabinoids from high potency Cannabis sativa. Phytochemistry 117:194–199. https://doi.org/10.1016/j.phytochem.2015.04.007
Alberti TB, Barbosa WL, Vieira JL et al (2017) (−)-β-Caryophyllene, a CB2 receptor-selective phytocannabinoid, suppresses motor paralysis and neuroinflammation in a murine model of multiple sclerosis. Int J Mol Sci 18:E691. https://doi.org/10.3390/ijms18040691
Amada N, Yamasaki Y, Williams CM et al (2013) Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. Peer J 1:e214. https://doi.org/10.7717/peerj.214
Avraham Y, Ben-Shushan D, Breuer A et al (2004) Very low doses of Δ8-THC increase food consumption and alter neurotransmitter levels following weight loss. Pharmacol Biochem Behav 77:675–684. https://doi.org/10.1016/j.pbb.2004.01.015
Babson KA, Sottile J, Morabito D (2017) Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep 19:23. https://doi.org/10.1007/s11920-017-0775-9
Bahi A, Al Mansouri S, Al Memari E et al (2014) β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. Physiol Behav 135:119–124. https://doi.org/10.1016/j.physbeh.2014.06.003
Bambico FR, Hattan PR, Garant JP et al (2012) Effect of delta-9-tetrahydrocannabinol on behavioral despair and on pre- and postsynaptic serotonergic transmission. Prog Neuro-Psychopharmacol Biol Psychiatry 38:88–96. https://doi.org/10.1016/j.pnpbp.2012.02.006
Baron EP, Lucas P, Eades J et al (2018) Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain 19:37. https://doi.org/10.1186/s10194-018-0862-2
Bergamaschi MM, Queiroz RH, Chagas MH et al (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36:1219–1226. https://doi.org/10.1038/npp.2011.6
Betthauser K, Pilz J, Vollmer LE (2015) Use and effects of cannabinoids in military veterans with posttraumatic stress disorder. Am J Health Syst Pharm 72:1279–1284. https://doi.org/10.2146/ajhp140523
Bhattacharyya S, Morrison PD, Fusar-Poli P et al (2010) Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:764–774. https://doi.org/10.1038/npp.2009.184
Bisogno T, Hanus L, De Petrocellis L (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845–852. https://doi.org/10.1038/sj.bjp.0704327
Bolognini D, Costa B, Maione S et al (2010) The plant cannabinoid Δ9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol 160:677–687. https://doi.org/10.1111/j.1476-5381.2010.00756.x
Bolognini D, Rock EM, Cluny NL et al (2013) Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 168:1456–1470. https://doi.org/10.1111/bph.12043
Borrelli F, Fasolino I, Romano B et al (2013) Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol 85:1306–1316. https://doi.org/10.1016/j.bcp.2013.01.017
Brenneisen R (2007) Chemistry and analysis of phytocannabinoids and other cannabis constituents. In: ElSohly M (ed) Marijuana and the cannabinoids forensic science and medicine. Humana Press, New York, pp 17–49
Brierley DI, Samuels J, Duncan M et al (2016) Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. Psychopharmacology 233:3603–3613. https://doi.org/10.1007/s00213-016-4397-4
Brierley DI, Samuels J, Duncan M et al (2017) A cannabigerol-rich Cannabis sativa extract, devoid of 9-tetrahydrocannabinol, elicits hyperphagia in rats. Behav Pharmacol 28:280–284. https://doi.org/10.1097/FBP.0000000000000285
Carcieri C, Tomasello C, Simiele M et al (2018) Cannabinoids concentration variability in cannabis olive oil galenic preparations. J Pharm Pharmacol 70:143–149. https://doi.org/10.1111/jphp.12845
Cascio MG, Gauson LA, Stevenson LA et al (2010) Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol 159:129–141. https://doi.org/10.1111/j.1476-5381.2009.00515.x
Chagas MH, Zuardi AW, Tumas V et al (2014) Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol 28:1088–1098. https://doi.org/10.1177/0269881114550355
Chang AE, Shiling DJ, Stillman RC et al (1979) Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 91:819–824
Cheng D, Low JK, Logge W et al (2014) Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1E9 mice. Psychopharmacology 231:3009–3017. https://doi.org/10.1007/s00213-014-3478-5
Cichewicz DL, Martin ZL, Smith FL et al (1999) Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther 289:859–867
Citti C, Ciccarella G, Braghiroli D et al (2016) Medicinal cannabis: principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. J Pharm Biomed Anal 128:201–209. https://doi.org/10.1016/j.jpba.2016.05.033
Cleemput MV, Cattoor K, Bosscher KD et al (2009) Hop (Humulus lupulus)-derived bitter acids as multipotent bioactive compounds. J Nat Prod 72:1220–1230. https://doi.org/10.1021/np800740m
Cluny NL, Naylor RJ, Whittle BA et al (2008) The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus. Basic Clin Pharmacol Toxicol 103:150–156. https://doi.org/10.1111/j.1742-7843.2008.00253.x
Costa B, Comelli F (2014) Pain. In: Pertwee RG (ed) Handbook of cannabis. Oxford University Press, United Kingdom, pp 473–486
Crippa JA, Derenusson GN, Ferrari TB et al (2011) Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 25:121–130. https://doi.org/10.1177/0269881110379283
Crippa JA, Guimarães FS, Campos AC et al (2018) Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Front Immunol 9:2009. https://doi.org/10.3389/fimmu.2018.02009
Cunha JM, Carlini EA, Pereira AE et al (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21:175–185
de Cássia da Silveira E Sá R, Lima TC, da Nóbrega FR et al (2017) Analgesic-like activity of essential oil constituents: an update. Int J Mol Sci 18:E2392. https://doi.org/10.3390/ijms18122392
de Oliveira DR, da Silva DM, Florentino IF et al (2018) Monoamine involvement in the antidepressant-like effect of β-caryophyllene. CNS Neurol Disord Drug Targets 17:309–320. https://doi.org/10.2174/1871527317666180420150249
De Petrocellis L, Ligresti A, Moriello AS et al (2011) Effects of cannabinoids and cannabinoid-enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163:1479–1494. https://doi.org/10.1111/j.1476-5381.2010.01166.x
De Petrocellis L, Orlando P, Moriello AS et al (2012) Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol 204:255–266. https://doi.org/10.1111/j.1748-1716.2011.02338.x
De Petrocellis L, Vellani V, Schiano-Moriello A et al (2008) Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther 325:1007–1015. https://doi.org/10.1124/jpet.107.134809
Devane WA, Dysarz FA, Johnson MR et al (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605–613
Devane WA, Hanus L, Breuer A et al (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949
Devinsky O, Cross JH, Laux L et al (2017) Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 376:2011–2020. https://doi.org/10.1056/NEJMoa1611618
Edery H, Grunfeld Y, Ben-Zvi Z et al (1971) Structural requirements for cannabinoid activity. Ann N Y Acad Sci 191:40–53
Edery H, Grunfeld Y, Porath G et al (1972) Structure-activity relationships in the tetrahydrocannabinol series. Modifications on the aromatic ring and it the side-chain. Arzneimittelforschung 22:1995–2003
Einhorn LH, Nagy C, Furnas B et al (1981) Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol 21:64–69
ElSohl MA, Gul W (2014) Constituents of Cannabis sativa. In: Pertwee RG (ed) Handbook of cannabis. Oxford University Press, UK, pp 3–22
ElSohly MA, Mehmedic Z, Foster S et al (2016) Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry 79:613–619. https://doi.org/10.1016/j.biopsych.2016.01.004
ElSohly MA, Slade D (2005) Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 78:539–548. https://doi.org/10.1016/j.lfs.2005.09.011
Felipe CFB, Albuquerque AMS, de Pontes JLX et al (2018) Comparative study of alpha- and beta-pinene effect on PTZ-induced convulsions in mice. Fundam Clin Pharmacol 33(2):181–190. https://doi.org/10.1111/fcp.12416
Fraguas-Sánchez AI, Torres-Suárez AI (2018) Medical use of cannabinoids. Drugs 78:1665–1703. https://doi.org/10.1007/s40265-018-0996-1
Frytak S, Moertel CG, O’Fallon JR et al (1979) Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med 91:825–830
Gaoni Y, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646–1647
Gertsch J, Leonti M, Raduner S et al (2008) Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A 105:9099–9104. https://doi.org/10.1073/pnas.0803601105
Gill EW (1971) Propyl homologue of tetrahydrocannabinol: its isolation from cannabis, properties, and synthesis. J Chem Soc, Section C: Organic 0:579–582
Grunfeld Y, Edery H (1969) Psychopharmacological activity of the active constituents of hashish and some related cannabinoids. Psychopharmacologia 14:200–210
Gugliandolo A, Pollastro F, Grassi G et al (2018) In vitro model of neuroinflammation: efficacy of cannabigerol, a non-psychoactive cannabinoid. Int J Mol Sci 19:E1992. https://doi.org/10.3390/ijms19071992
Guimarães FS, Chiaretti TM, Graeff FG et al (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100:558–559. https://doi.org/10.1007/BF02244012
Hanuš L, Krejčí Z (1975) Isolation of two new cannabinoid acids from Cannabis sativa L. of Czechoslovak origin. Acta Univ Olomuc Fac Med 74:161–166
Herman TS, Einhorn LH, Jones SE et al (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300:1295–1297
Herman TS, Jones SE, Dean J et al (1977) Nabilone: a potent antiemetic cannabinol with minimal euphoria. Biomedicine 27:331–334
Hill TD, Cascio MG, Romano B et al (2013) Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol 170:679–692. https://doi.org/10.1111/bph.12321
Hill MN, Gorzalka BB (2004) Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. Eur J Pharmacol 499:291–295. https://doi.org/10.1016/j.ejphar.2004.06.069
Hill AJ, Mercier MS, Hill TD et al (2012) Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol 167:1629–1642. https://doi.org/10.1111/j.1476-5381.2012.02207.x
Hively RL, Mosher WA, Hoffmann FW (1966) Isolation of trans-Δ6-tetrahydrocannabinol from marijuana. J Am Chem Soc 88:1832–1833
Hollister LE (1974) Structure-activity relationships in man of cannabis constituents, and homologs and metabolites of delta9-tetrahydrocannabinol. Pharmacology 11:3–11
Howlett AC, Qualy JM, Khachatrian LL (1986) Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29:307–313
Huffman JW, Liddle J, Yu S et al (1999) 3-(1′,1′-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7:2905–2914
Husni AS, McCurdy CR, Radwan MM et al (2014) Evaluation of phytocannabinoids from high potency Cannabis sativa using in vitro bioassays to determine structure-activity relationships for cannabinoid receptor 1 and cannabinoid receptor 2. Med Chem Res 23:4295–4300. https://10.1007/s00044-014-0972-6
Izzo AA, Borrelli F, Capasso R (2009) Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30:515–527. https://10.1016/j.tips.2009.07.00
Jacobs DS, Kohut SJ, Jiang S et al (2016) Acute and chronic effects of cannabidiol on Δ9-tetrahydrocannabinol (Δ9-THC)-induced disruption in stop signal task performance. Exp Clin Psychopharmacol 24:320–330. https://10.1037/pha0000081
Jamontt JM, Molleman A, Pertwee RG et al (2010) The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol 160:712–723. https://10.1111/j.1476-5381.2010.00791.x
Jetly R, Heber A, Fraser G et al (2015) The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 51:585–588. https://10.1016/j.psyneuen.2014.11.002
Kennedy DO, Dodd FL, Robertson BC et al (2011) Monoterpenoid extract of sage (salvia lavandulaefolia) with cholinesterase inhibiting properties improves cognitive performance and mood in healthy adults. J Psychopharmacol 25:1088–1100. https://10.1177/0269881110385594
Kim DS, Lee HJ, Jeon YD et al (2015) Alpha-pinene exhibits anti-inflammatory activity through the suppression of MAPKs and the NF-κB pathway in mouse peritoneal macrophages. Am J Chin Med 43:731–742. https://10.1142/S0192415X15500457
Komori T, Fujiwara R, Tanida M et al (1995) Effects of citrus fragrance on immune function and depressive states. Neuroimmunology 2:174–180. https://10.1159/000096889
Louw DF, Yang FW, Sutherland GR (2000) The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res 857:183–187. https://doi.org/10.1016/S0006-8993(99)02422-1
Lynch ME, Clark AJ (2003) Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. J Pain Symptom Manag 25:496–498. https://doi.org/10.1016/S0885-3924(03)00142-8
Martin BR, Compton DR, Thomas BF et al (1991) Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40:471–478
McGuire P, Robson P, Cubala WJ et al (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175:225–231. https://doi.org/10.1176/appi.ajp.2017.17030325
McPartland JM, MacDonald C, Young M et al (2017) Affinity and efficacy studies of tetrahydrocannabinolic acid a at cannabinoid receptor types one and two. Cannabis Cannabinoid Res 2:87–95. https://10.1089/can.2016.0032
McPartland JM, Russo EB (2001) Cannabis and cannabis extracts: greater than the sum of their parts? J Cann Therap 1:103–132. https://doi.org/10.1300/J175v01n03_08
Mechoulam R (2005) Plant cannabinoids: a neglected pharmacological treasure trove. Br J Pharmacol 146:913–915. https://doi.org/10.1038/sj.bjp.0706415
Mechoulam R, Ben-Shabat S, Hanus L et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83–90. https://doi.org/10.1016/0006-2952(95)00109-D
Mechoulam R, Ben-Zvi Z, Yagnitinsky B et al (1969) A new tetrahydrocannabinolic acid. Tetrahedron Lett 28:2339–2341
Mechoulam R, Hanus LO, Pertwee R et al (2014) Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci 15:757–764. https://doi.org/10.1038/nrn3811
Mechoulam R, Shani A, Edery H et al (1970) Chemical basis of hashish activity. Science 169:611–612
Mechoulam R, Shvo Y (1963) Hashish. I. the structure of cannabidiol. Tetrahedron 19:2073–2078
Meier C, Mediavilla V (1998) Factors influencing the yield and the quality of hemp (Cannabis sativa L.) essential oil. J Int Hemp Assoc 5:16–20
Merkus FWHM (1971) Cannabivarin and tetrahydrocannabivarin, two new constituents of hashish. Nature 232:579–580
Merli F, Novotny M, Lee ML (1980) Fractionation and gas chromatographic analysis of aza-arenes in complex mixtures. J Chromatogr 199:371–378. https://doi.org/10.1016/S0021-9673(01)91388-3
Morales P, Hurst DP, Reggio PH (2017) Molecular targets of the phytocannabinoids: a complex picture. Prog Chem Org Nat Prod 103:103–131. https://doi.org/10.1007/978-3-319-45541-9_4
Moreno-Sanz G (2016) Can you pass the acid test? Critical review and novel therapeutic perspectives of Δ9-tetrahydrocannabinolic acid a. Cannabis Cannabinoid Res 1:124–130. https://doi.org/10.1089/can.2016.0008
Müller-Vahl KR, Schneider U, Koblenz A et al (2002) Treatment of Tourette’s syndrome with delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 3:57–61. https://doi.org/10.1055/s-2002-25028
Müller-Vahl KR, Schneider U, Prevedel H et al (2003) Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6- week randomized trial. J Clin Psychiatry 64:459–465
Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65. https://doi.org/10.1038/365061a0
Nelson K, Walsh D, Deeter P et al (1994) A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 10:14–18
O’Brien LD, Wills KL, Segsworth B et al (2013) Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability. Pharmacol Biochem Behav 103:597–602. https://doi.org/10.1016/j.pbb.2012.10.008
Parker LA, Kwiatkowska M, Burton P et al (2004) Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology 171:156–161. https://doi.org/10.1007/s00213-003-1571-2
Parker LA, Mechoulam R, Schlievert C et al (2003) Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology 166:156–162. https://doi.org/10.1007/s00213-002-1329-2
Pate DW (1994) Chemical ecology of cannabis. J Int Hemp Association 2(29):32–37
Pedersen W, Sandberg S (2013) The medicalisation of revolt: a sociological analysis of medical cannabis users. Sociol Health Illn 35:17–32. https://doi.org/10.1111/j.1467-9566.2012.01476.x
Pellesi L, Licata M, Verri P et al (2018) Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)—a pilot study. Eur J Clin Pharmacol 74:1427–1436. https://doi.org/10.1007/s00228-018-2516-3
Pertwee RG (1972) The ring test: a quantitative method for assessing the ‘cataleptic’ effect of cannabis in mice. Br J Pharmacol 46:753–763
Pertwee RG (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307–1324. https://doi.org/10.1016/j.lfs.2004.10.025
Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol 153:199–215. https://doi.org/10.1038/sj.bjp.0707442
Pertwee RG, Thomas A, Stevenson LA et al (2007) The psychoactive plant cannabinoid, delta9-tetrahydrocannabinol, is antagonized by delta8- and delta9- tetrahydrocannabivarin in mice in vivo. Br J Pharmacol 150:586–594. https://doi.org/10.1038/sj.bjp.0707124
Raman C, McAllister SD, Rizvi G (2004) Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord 5:33–39. https://doi.org/10.1080/14660820310016813
Razdan RK (1986) Structure-activity relationships in cannabinoids. Pharmacol Rev 38:75–149
Riedel G, Fadda P, McKillop-Smith S (2009) Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol 156:1154–1166. https://doi.org/10.1111/j.1476-5381.2008.00107.x
Rock EM, Bolognini D, Limebeer CL et al (2012) Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 165:2620–2634. https://doi.org/10.1111/j.1476-5381.2011.01621.x
Rock EM, Connolly C, Limebeer CL et al (2016) Effect of combined oral doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea in rat models. Psychopharmacology 233:3353–3360. https://doi.org/10.1007/s00213-016-4378-7
Rock EM, Goodwin JM, Limebeer CL et al (2011) Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology 215:505–512. https://doi.org/10.1007/s00213-010-2157-4
Rock EM, Kopstick RL, Limebeer CL et al (2013a) Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus. Br J Pharmacol 170:641–648. https://doi.org/10.1111/bph.12316
Rock EM, Limebeer CL, Navaratnam R (2014a) A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping. Psychopharmacology 231:3207–3215. https://doi.org/10.1007/s00213-014-3498-1
Rock EM, Limebeer CL, Parker LA (2014b) Anticipatory nausea in animal models: a review of potential novel therapeutic treatments. Exp Brain Res 232:2511–2534. https://doi.org/10.1007/s00221-014-3942-9
Rock EM, Limebeer CL, Parker LA (2015) Effect of combined doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat (Sprague-Dawley) models of conditioned gaping. Psychopharmacology 232:4445–4454. https://doi.org/10.1007/s00213-015-4080-1
Rock EM, Limebeer CL, Parker LA (2018) Effect of cannabidiolic acid and Δ9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain. Psychopharmacology 235:3259–3271. https://doi.org/10.1007/s00213-018-5034-1
Rock EM, Limebeer CL, Petrie GN et al (2017) Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats. Psychopharmacology 234:2207–2217. https://doi.org/10.1007/s00213-017-4626-5
Rock EM, Parker LA (2015) Synergy between cannabidiol, cannabidiolic acid, and Δ9-tetrahydrocannabinol in the regulation of emesis in the Suncus murinus (house musk shrew). Behav Neurosci 129:368–370. https://doi.org/10.1037/bne0000057
Rock EM, Sticht MA, Duncan M et al (2013b) Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. Br J Pharmacol 170:671–678. https://doi.org/10.1111/bph.12322
Rosenthaler S, Pöhn B, Kolmanz C et al (2014) Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures. Neurotoxicol Teratol 46:49–56. https://doi.org/10.1016/j.ntt.2014.09.003
Rothschild M, Bergstrom G, Wangberg S (2005) Cannabis sativa: volatile compounds from pollen and entire male and female plants of two variants, northern lights and Hawaian Indica. Bot J Linn Soc 147:387–397. https://doi.org/1111/j.1095-8339.2005.00417.x
Russo EB (2011) Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163:1344–1364. https://doi.org/10.1111/j.1476-5381.2011.01238.x
Russo EB, Burnett A, Hall B et al (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30:1037–1043. https://doi.org/10.1007/s11064-005-6978-1
Segat GC, Manjavachi MN, Matias DO et al (2017) Antiallodynic effect of β-caryophyllene on paclitaxel-induced peripheral neuropathy in mice. Neuropharmacology 125:207–219. https://doi.org/10.1016/j.neuropharm.2017.07.015
Singh B, Sharma R (2015) Plant terpenes: defense responses, phylogenetic analysis, regulation and clinical applications. 3 Biotech 5:129–151. https://doi.org/10.1007/s13205-014-0220-2
Sjödén PO, Järbe TU, Henriksson BG (1973) Influence of tetrahydrocannabinols (delta8-THC and delta9-THC) on body weight, food, and water intake in rats. Pharmacol Biochem Behav 1:395–399
Smith RN, Vaughan CG (1977) The decomposition of acidic and neutral cannabinoids in organic solvents. J Pharm Pharmacol 29:286–290
Sugiura T, Kondo S, Sukagawa A et al (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215:89–97. https://doi.org/10.1006/bbrc.1995.2437
Szaflarski JP, Bebin EM, Comi AM et al (2018) Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia 59:1540–1548. https://doi.org/10.1111/epi.14477
Takeda S, Okajima S, Miyoshi H et al (2012) Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. Toxicol Lett 214:314–319. https://doi.org/10.1016/j.toxlet.2012.08.029
Tchekalarova J, da Conceição MK, Gomes Júnior AL et al (2011) Pharmacological characterization of the cannabinoid receptor 2 agonist, β-caryophyllene on seizure models in mice. Seizure 57:22–26. https://doi.org/10.1016/j.seizure.2018.03.009
Thomas GL, Baillie AM, Phillips RK et al (2007) Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150:613–623. https://doi.org/10.1038/sj.bjp.0707133
Uemura M, Hata GI, Toda T et al (1997) Effectiveness of eucalyptol and d-limonene as gutta-percha solvents. J Endod 23:739–741. https://doi.org/10.1016/S0099-2399(97)80346-9
Valdeolivas S, Navarrete C, Cantarero I (2015) Neuroprotective properties of cannabigerol in Huntington’s disease: studies in r6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics 12:185–199. https://doi.org/10.1007/s13311-014-0304-z
van Vliet SA, Vanwersch RA, Jongsma MJ et al (2008) Therapeutic effects of delta9-THC and modafinil in a marmoset Parkinson model. Eur Neuropsychopharmacol 18:383–389. https://doi.org/10.1016/j.euroneuro.2007.11.003
Verhoeckx KC, Korthout HA, van Meeteren-Kreikamp AP (2006) Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int Immunopharmacol 6:656–665. https://doi.org/10.1016/j.intimp.2005.10.002
Vigli D, Cosentino L, Raggi C et al (2018) Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome. Neuropharmacology 140:121–129. https://doi.org/10.1016/j.neuropharm.2018.07.029
Ware MA, Wang T, Shapiro S et al (2010) Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 182:E694–E701. https://doi.org/10.1503/cmaj.091414
Wilsey B, Marcotte T, Deutsch R et al (2013) Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain 14:136–148. https://doi.org/10.1016/j.jpain.2012.10.009
Wilsey B, Marcotte T, Tsodikov A et al (2008) A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 9:506–521. https://doi.org/10.1016/j.jpain.2007.12.010
Yang M, Lv Y, Tian X et al (2017) Neuroprotective effect of β-caryophyllene on cerebral ischemia-reperfusion injury via regulation of necroptotic neuronal death and inflammation: in vivo and in vitro. Front Neurosci 11:583. https://doi.org/10.3389/fnins.2017.00583
Yun J (2014) Limonene inhibits methamphetamine-induced locomotor activity via regulation of 5-HT neuronal function and dopamine release. Phytomedicine 21:883–887. https://doi.org/10.1016/j.phymed.2013.12.004
Zanelati TV, Biojone C, Moreira FA et al (2010) Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 159:122–128. https://doi.org/10.1111/j.1476-5381.2009.00521.x
Zhao Y, Chen R, Wang Y et al (2018) α-Pinene inhibits human prostate cancer growth in a mouse xenograft model. Chemotherapy 63:1–7. https://doi.org/10.1159/000479863
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rock, E.M., Parker, L.A. (2021). Constituents of Cannabis Sativa. In: Murillo-Rodriguez, E., Pandi-Perumal, S.R., Monti, J.M. (eds) Cannabinoids and Neuropsychiatric Disorders. Advances in Experimental Medicine and Biology, vol 1264. Springer, Cham. https://doi.org/10.1007/978-3-030-57369-0_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-57369-0_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-57368-3
Online ISBN: 978-3-030-57369-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)